A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)
A Registry of Patients With Primary Choroidal Melanoma (CM) or Indeterminate Lesions (ILs)
The purpose of this observational research study is to follow participants who have been
 treated with either AU-011 or observation and/or received standard of care therapy while
 participating in a previous Aura Biosciences clinical research study to assess the long-term
 safety and effectiveness of AU-011 and standard of care therapy. This study will collect
 information from procedures conducted as part of routine follow-up eye care and cancer care.
This is a multi-center long-term observational Registry of patients with Primary Choroidal
 Melanoma (CM) or Indeterminate Lesions (ILs) The Registry will initially be open to patients
 who have previously participated in an Aura Biosciences sponsored clinical trial for their
 primary Choroidal Melanoma or Indeterminate Lesions.

 All patients will be followed for a minimum of 5 years (including time enrolled in an Aura
 sponsored clinical trial), until withdrawal of consent, or until death whichever comes first.

 No interventions will be required as part of the Registry. Data collection will be based on
 information anticipated to be available based on the standard of care for patients with CM or
 IL; these patients are routinely followed at 6-month intervals by their treating physician.
Inclusion Criteria:

 -  Have been clinically diagnosed with primary CM or IL at the time of entry to a
 previous Aura Biosciences sponsored clinical trial.

 -  Have received AU-011 or assigned to an observation cohort in a previous Aura sponsored
 clinical trial.

 Exclusion Criteria:

 -  None